concern on-q cautiou
margin progress new erp suppli chain issu
continu delay recoveri on-q like extend
overhang share remain underweight pt
report revenu mse consensu
impli pt underli momentum deceler miss driven
product back order suppli chain challeng stem erp
implement challeng discuss implic
throughout came pt light vs mse om
miss bp vs mse ep fell nearli short
expect vs mse miss stem chronic
organ basi although typic steadi msd
growth busi pain manag perform in-lin preview
organ growth evidenc rel steadi on-q result q/q
coolief growth given inventori suppli dynam avano lower
cc growth guidanc vs prior last rais
although effect repres narrow low-end origin
rang absent contribut see analysi avano also lower
ep guidanc midpoint
model pleas see exhibit full reconcili result vs mse
three key focu area sever issu drove miss guide-down primarili
isol within chronic pain manag less impact
chronic back order across avano domest
intern region associ implement compani
new erp system announc last quarter drive half quarterli
top-line miss unexpect distributor inventori drawdown
drive revenu shortfal avano intern region partial
associ re-brand product halyard avano
manag identifi issu work resolv system
implement drive sequenti improv chronic
result howev growth may return market
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
avano like exit toward low-end msd growth chronic
model
on-q still pain point on-q worsen quarter despit
rel q/q stabil ropivacain suppli come back on-line
hospira earli octob manag anticip quarter
recaptur meaning piec lost custom base
like reflect demand issu discuss last quarter manag
forecast on-q busi grow lsd vs msd
model consist flat on-q sale improv
lsd growth back half
coolief bright spot coolief grew direct-to-pati
dtp invest paid dividend sens avano exit year
similar level impli high-teen coolief growth despit
higher reimburs outpati set see note
sens coolief growth look similar y/i in-
offic payment chang enough shift adopt away
hospit addit roughli coolief procedur today
cover privat payor manag expect could year
privat payor adopt increas pay rate remain encourag
coolief futur prospect time meaning
reimburs chang competit enter space two
like level uncertainti remain come quarter given
avano continu oper without cfo sinc steve voskuil depart
april challeng segment busi continu mid-
street high less construct
rel consensu investor focus turn on-q
busi earli like cost transform
plan regain steam expect mute margin impact given
top-line challeng compens chang expect meaning off-set
cost save consist manag commentari discuss
model lsd acut pain growth msd growth previous
prudent expect chronic challeng continu net
model cc growth impli organ growth reflect
bp y/i momentum acceler oper margin preview
bp expans sens would look
similar rel bp expans model street
follow today commentari lower level expans like
bp rang expect street number come
bp pleas see exhibit summar model chang
remain underweight pt today issu come meaning surpris
even rel conserv estim although
piec pain manag busi on-track coolief
manag expect chronic issu resolv cours
quarter challeng forc continu delay execut post- ip
transform target lower price target reflect
new ebitda estim discount smid med-tech coverag
could becom posit avano follow inventori supply-chain
follow recent revis reimburs drive growth
attract valuat near-term headwind keep us cautiou
deriv base case scenario price target reflect
ev ebitda multipl discount smid med-tech
coverag given lower organ growth partial off-set signific
margin expans opportun year
market reward avano accret deal near-term recoveri on-q
avano execut larg acquisit drive growth earn accret
growth restructur plan progress accord plan
transform proce estim high avano return msd
organ growth follow on-q suppli headwind path
toward oper margin improv move forward plan
restructur prove challeng medic devic sale growth low/mid
singl digit restructur initi yield expect benefit lead
lower earn level
transform price
believ investor alreadi price
major benefit associ cost
transform risk near-term
revenu headwind make upsid mid-
includ continu headwind within
challeng chronic expect
resolv earli competit
materi upsid requir
limit visibl time divestitur
 ip leav avano signific capac
execut deal execut deal
corpak-lik profil drive bull case
deploy half deal capac could drive
ebitda accret ep accret
everi cost save dis-
synergi worth ep
growth on-q drive pt corpor
restructur execut
risk achiev price
signific near-term recoveri on-q pain
avano execut larg accret
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
good sold
dollar million except per share data
cash equival
current defer incom tax
properti plant equip net
accumul comprehens incom loss
dollar million except per share data
depreci amort
share-bas compens charg
provis loss account receiv inventori
net loss asset disposit
chang oper work capit
prepaid expens asset
acquisit invest
disposit properti
invest activ
chang net invest
financ activ
effect exchang rate chang
begin period
end period
